The innovative software "CAAS vFFR" by PMI for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III
PR93529
The innovative software "CAAS vFFR" by Pie Medical Imaging for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III, a multicenter European clinical trial which will investigate the effectiveness of the vessel Fractional Flow Reserve (vFFR) guided revascularization as compared to conventional FFR guided revascularization
MAASTRICHT, Netherlands, December 12, 2021 /PRNewswire=KYODO JBN/--
Pie Medical Imaging ("PMI"), a global leader in cardiac imaging, part of the
Esaote Group, today announced the beginning of FASTIII, a multicenter
randomized clinical trial which will investigate the use of angiography-based
vessel fractional flow reserve (CAAS vFFR) in patients undergoing coronary
revascularization procedures.
The FASTIII trial, that is led by Dr. Joost Daemen (cardiologist at the
Thoraxcenter at the Erasmus University Medical Center, Rotterdam, The
Netherlands), is an investigator initiated international, multi-center
randomized, non-inferiority trial aiming to enroll a total of 2228 patients, in
7 European countries and 35 hospitals and is sponsored by the European
Cardiovascular Research Institute (ECRI).
The FAST III study aims to demonstrate non-inferiority of CAAS vFFR guided
revascularization as compared to a conventional invasive wire based FFR guided
revascularization in patients with either stable coronary syndrome or non-ST
segment elevation myocardial infarction and intermediate coronary artery
lesions.
vFFR can assess whether a coronary artery narrowing is functionally severe and
requires treatment. CAAS vFFR allows doing so without the need of invasive
wires- that are part of the routine practice to measure pressure gradients
(FFR) – and adenosine.
The high diagnostic accuracy of CAAS vFFR, which calculates pressure drop and
vFFR value using angiography images only was recently confirmed by the results
of FAST I, FAST Extend and FASTII studies which validated vFFR as an accurate
and easy to use tool to assess coronary physiology.
"We are confident that this new study will lead to a broader use of methods
based on angiographic images for a safe and accurate assessment of severity and
percentage of artery stenosis" said René Guillaume, PMI Managing Director.
The trial is funded by research grants from Pie Medical Imaging (Maastricht,
the Netherlands) and Siemens Healthineers GmbH (Erlangen, Germany).
About Pie Medical Imaging
Pie Medical Imaging BV is a world leader in analysis and visualization of
cardiovascular images in Maastricht (The Netherlands), it hosts the global
sales for the CAAS and 3mensio product lines. PMI and 3mensio Medical Imaging
are part of the Esaote Group, leader in the biomedical equipment sector. More
information about PMI is available at www.piemedicalimaging.com
Photo -
https://mma.prnewswire.com/media/1704306/CAAS_vFFR_real_time_cathlab.jpg
Logo - https://mma.prnewswire.com/media/1511581/PMI__Logo.jpg
SOURCE: Pie Medical Imaging
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。